Propofol vs Sevo for Paediatric Tumor Surgery
Keywords
Abstract
Description
Surgical resection is the main modality of treatment for many solid tumors. Despite successful tumor resection, some patients develop local recurrence or metastasis, causing morbidities and mortality. In recent years, there is growing interest in the pathophysiology of recurrence or metastasis. It is believed that the recurrence is caused by the liberation of circulating tumor cells during surgical manipulation of the tumors and the vascular invasive properties of the tumor cells. Perioperative events, such as surgical stress and anaesthesia may have immunomodulating effects, causing growth or inhibition of circulating tumor cells, which affect disease relapse. There is growing evidence that propofol is anti-inflammatory while sevoflurane is pro-inflammatory and their potential roles in cancer recurrence attract researchers' attention. In adults, there is increasing number of researches showing that propofol may improve patient outcomes in terms of disease survival, when compared to sevoflurane. However, such evidence in paediatric population is lacking. This study aims to compare the effects of propofol based intravenous anaesthesia with inhalation anaesthesia with sevoflurane on perioperative biomarkers of inflammation, circulating tumor cells and disease free survival in 3 years.
100 patients will be recruited for this single blinded randomised controlled trial. They will receive general anaesthesia in Hong Kong Children's Hospital for their primary tumor excision surgery. 50 patients will be randomised to sevoflurane group and 50 patients will be randomised to propofol group. They will receive standardised anaesthetic management in terms of death or anaesthesia, pain management, fluid or thermoregulation management. Sevoflurane group subjects will receive inhalational sevoflurane as main anaesthetic, while propofol group subjects will receive intravenous propofol. These patients will have 4 blood tests collected for analysis for biomarkers of inflammation, DNA damage, oxidative stress and circulating tumor cells.
- baseline: once patients have intravenous access established
- intraoperative: when the tumor is deemed resected by surgeons
- immediately postop: after wound closure
- 24 hours postop Early postoperative period follow up will look for wound recovery, sepsis, and time to start chemotherapy and need for second look operation for wound complication.
Patients will also followed up for 3 years for tumor recurrence and disease survival.
Dates
| Last Verified: | 06/30/2020 |
| First Submitted: | 07/06/2020 |
| Estimated Enrollment Submitted: | 07/13/2020 |
| First Posted: | 07/16/2020 |
| Last Update Submitted: | 07/13/2020 |
| Last Update Posted: | 07/16/2020 |
| Actual Study Start Date: | 06/30/2020 |
| Estimated Primary Completion Date: | 06/30/2028 |
| Estimated Study Completion Date: | 06/30/2028 |
Condition or disease
Intervention/treatment
Drug: propofol group
Drug: Sevoflurane group
Phase
Arm Groups
| Arm | Intervention/treatment |
|---|---|
| Active Comparator: Sevoflurane group patients in this group will receive inhalation anaesthesia with sevoflurane at Minimal Alveolar Concentration 0.7-1.3 as the main anaesthetic to achieve Bispectral Index 40-60. Other anaesthetic management will be standardised. | Drug: Sevoflurane group sevoflurane at Minimal Alveolar Concentration 0.7-1.3 as the main anaesthetic to achieve Bispectral Index 40-60. |
| Active Comparator: propofol group patients in this group will receive intravenous propofol using Target Controlled Infusion 'Paedfusor' model 2-5 as the main anaesthetic to achieve Bispectral Index 40-60. Other anaesthetic management will be standardised. | Drug: propofol group intravenous propofol using Target Controlled Infusion 'Paedfusor' model 2-5 as the main anaesthetic to achieve Bispectral Index 40-60 |
Eligibility Criteria
| Ages Eligible for Study | 6 Months To 6 Months |
| Sexes Eligible for Study | All |
| Accepts Healthy Volunteers | Yes |
| Criteria | Inclusion Criteria: - patients coming for elective primary solid tumor resection for curative intent in Hong Kong Children's Hospital - AND patients > 5kg - AND patients within age limit Exclusion Criteria: - Autoimmune / Chronic inflammatory diseases e.g. Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA) etc. - Current Steroid therapy - Surgery for tumour removal in the past year - Allergy to Propofol - intraoperative use of nitrous oxide - Patient susceptible to Malignant Hyperthermia - Patients / parents / legal guardians showing preference in anaesthetic techniques during recruitment process |
Outcome
Primary Outcome Measures
1. difference in Hypoxia Inducible Factor-1 gene expression [intraoperative to postoperative 24 hours]
Secondary Outcome Measures
1. difference in levels of Interleukin-6 [intraoperative to postoperative 24 hours]
2. difference in levels of Tumor Necrosis Factor-alpha [intraoperative to postoperative 24 hours]
3. difference in levels of high sensitivity C reaction protein [intraoperative to postoperative 24 hours]
4. difference in levels of DNA damage (Comet Assay) [intraoperative to postoperative 24 hours]
5. difference in levels of Glutathione Peroxidase [intraoperative to postoperative 24 hours]
6. difference in levels of Superoxide dismutase [intraoperative to postoperative 24 hours]
7. difference in levels of urinary 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG) [intraoperative to postoperative 24 hours]
8. difference in levels of 8-oxo-7,8-dihydroguanosine (8-oxoGuo) [intraoperative to postoperative 24 hours]
9. difference in the quantity of circulating tumor cells (CTC) [intraoperative to postoperative 24 hours]
10. cancer free survival at 1 and 3 years [intraoperative to postoperative 24 hours]
